CHAIR
:
SPEAKER
(S):
Frank Bennett, PhD, Senior Vice President, Research , Isis Pharmaceuticals, Inc
Dalia Cohen, PhD, Executive Vice President, Head of Global Research and Development , Rosetta Genomics LTD
Mark Davis, PhD, Founder, Calando Pharmaceuticals; Warren and Katharine Schlinger Professor of Chemical Engineering , Calando
John Maraganore, PhD, CEO , Alnylam Pharmaceuticals, Inc
Description
"Specifically interfering with messenger RNA is a powerful approach to prevent a disease-causing protein from being made and it offers the opportunity for the development of
novel, targeted therapeutics. Recent advances in RNA biology have lead to the development of molecules that inhibit mRNA and microRNA. This panel will focus on the development of oligonucleotide therapeutics and will discuss the challenges and opportunities of RNA-inhibiting drugs. Members of the panel are top executives from companies currently engaged in nucleic acid therapeutics and will be able to cite from experience the ongoing issues facing the development of the next pharmaceutical revolution."
Objective1:Address topical issues relating to advances in oligonucleotide-based therapeutics.
Objective2: Highlight the key breakthroughs in RNAi, microRNA and oligonucleotide-based therapeutics.
Objective3: Discuss the challenges companies face to commercialize these therapeutics.